{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:45:31Z","timestamp":1791852331677,"version":"4.3.4"},"reference-count":40,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Monitoring of Immune Responses Following Mogamulizumab-Containing Treatment in Patients with Adult T-Cell Leukemia-Lymphoma (ATL) (MIMOGA) is a multicenter prospective observational study to establish the most effective and safe treatment strategy using mogamulizumab for ATL patients (UMIN000008696). Mogamulizumab-naive patients were enrolled (n = 102), of whom 101 received mogamulizumab-containing treatment (68 acute, 18 lymphoma, 12 chronic, and 3 smoldering subtypes). At enrollment, there was a significant inverse correlation between serum soluble interleukin-2 receptor (sIL-2R) levels and percentages of Tax-specific cytotoxic T lymphocytes (Tax-CTLs) in the entire lymphocyte population or in the CD8+ T cell subset, but there was not a correlation with cytomegalovirus pp65\u2013specific cytotoxic T lymphocytes (CMV-CTLs). The overall response rate was 65%, and median progression-free survival and overall survival (OS) were 7.4 and 16.0 months, respectively. A higher percentage of Tax-CTLs, but not CMV-CTLs, within the entire lymphocyte population or in the CD8+ T cell subset was significantly associated with longer survival. Multivariate analysis identified the clinical subtype (acute or lymphoma type), a higher sIL-2R level, and a lower percentage of CD2\u2212CD19+ B cells in peripheral blood mononuclear cells as significant independent unfavorable prognostic factors for OS. This indicates that a higher percentage of B cells might reflect some aspect of a favorable immune status leading to a good outcome with mogamulizumab treatment. In conclusion, the MIMOGA study has demonstrated that mogamulizumab exerts clinically meaningful antitumor activity in ATL. The patient\u2019s immunological status before mogamulizumab was significantly associated with treatment outcome. Further time series immunological analyses, in addition to comprehensive genomic analyses, are warranted.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020003053","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T15:38:09Z","timestamp":1603381089000},"page":"5133-5145","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study"],"prefix":"10.1182","volume":"4","author":[{"given":"Kentaro","family":"Yonekura","sequence":"first","affiliation":[{"name":"Department of Hematology and"},{"name":"Department of Dermatology, Imamura General Hospital, Kagoshima, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6546-1279","authenticated-orcid":false,"given":"Shigeru","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asahi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youko","family":"Suehiro","sequence":"additional","affiliation":[{"name":"Department of Hematology and"},{"name":"Department of Cell Therapy, National Hospital Organization Kyushu Cancer Centre, Fukuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Imaizumi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5935-0385","authenticated-orcid":false,"given":"Makoto","family":"Yoshimitsu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kisato","family":"Nosaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Ohtsuka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita Prefectural Hospital, Oita, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Hidaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Hematology, and Infectious Diseases, Department of Medicine, Fukuoka University Hospital, Nagasaki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyoshi","family":"Moriuchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sasebo City General Hospital, Sasebo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4896-5878","authenticated-orcid":false,"given":"Masao","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita University Hospital, Oita, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiro","family":"Tatetsu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7030-497X","authenticated-orcid":false,"given":"Kenji","family":"Ishitsuka","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuzo","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Tumor Immunology, Aichi Medical University School of Medicine, Nagakute, Japan; and"},{"name":"Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atae","family":"Utsunomiya","sequence":"additional","affiliation":[{"name":"Department of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1060-0777","authenticated-orcid":false,"given":"Takashi","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan;"},{"name":"Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"issue":"5","key":"2020102211371717600_B1","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V99.5.1505","article-title":"Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells","volume":"99","author":"Yoshie","year":"2002","journal-title":"Blood"},{"issue":"10 Pt 1","key":"2020102211371717600_B2","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2020102211371717600_B3","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-04-0371","article-title":"CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2020102211371717600_B4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V96.2.685","article-title":"Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma","volume":"96","author":"Jones","year":"2000","journal-title":"Blood"},{"issue":"22","key":"2020102211371717600_B5","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1158\/1078-0432.CCR-04-0983","article-title":"The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-cell leukemia\/lymphoma","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2020102211371717600_B6","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","article-title":"Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma","volume":"16","author":"Ishii","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2020102211371717600_B7","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood"},{"issue":"8","key":"2020102211371717600_B8","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020102211371717600_B9","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol"},{"issue":"5","key":"2020102211371717600_B10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/cas.12116","article-title":"Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia\/lymphoma","volume":"104","author":"Ishida","year":"2013","journal-title":"Cancer Sci"},{"issue":"3","key":"2020102211371717600_B11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/hepr.12117","article-title":"Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab","volume":"44","author":"Nakano","year":"2014","journal-title":"Hepatol Res"},{"issue":"13","key":"2020102211371717600_B12","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/hepr.12513","article-title":"Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab","volume":"45","author":"Ifuku","year":"2015","journal-title":"Hepatol Res"},{"issue":"4","key":"2020102211371717600_B13","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjh.14634","article-title":"Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma","volume":"181","author":"Tokunaga","year":"2018","journal-title":"Br J Haematol"},{"issue":"10","key":"2020102211371717600_B14","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/cas.13343","article-title":"Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: Updated follow-up analysis of phase I and II studies","volume":"108","author":"Ishida","year":"2017","journal-title":"Cancer Sci"},{"issue":"14","key":"2020102211371717600_B15","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-2575","article-title":"Mogamulizumab treatment elicits autoantibodies attacking the skin in patients with adult T-Cell leukemia-lymphoma","volume":"25","author":"Suzuki","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2020102211371717600_B16","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/bloodadvances.2020001641","article-title":"Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma","volume":"4","author":"Saito","year":"2020","journal-title":"Blood Adv"},{"issue":"11","key":"2020102211371717600_B17","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/j.1349-7006.2006.00307.x","article-title":"CCR4 as a novel molecular target for immunotherapy of cancer","volume":"97","author":"Ishida","year":"2006","journal-title":"Cancer Sci"},{"issue":"3","key":"2020102211371717600_B18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/jjco\/hyv201","article-title":"Current status of immunotherapy","volume":"46","author":"Suzuki","year":"2016","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"2020102211371717600_B19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"issue":"3","key":"2020102211371717600_B20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","article-title":"Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting","volume":"27","author":"Tsukasaki","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"2020102211371717600_B21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1200\/JCO.18.00501","article-title":"Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report","volume":"37","author":"Cook","year":"2019","journal-title":"J Clin Oncol"},{"key":"2020102211371717600_B22","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3389\/fmicb.2019.02235","article-title":"Progress in allogeneic hematopoietic cell transplantation in adult T-cell leukemia-lymphoma","volume":"10","author":"Utsunomiya","year":"2019","journal-title":"Front Microbiol"},{"issue":"8","key":"2020102211371717600_B23","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2012-03-414490","article-title":"Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study","volume":"120","author":"Ishida","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2020102211371717600_B24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","article-title":"A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303","volume":"113","author":"Yamada","year":"2001","journal-title":"Br J Haematol"},{"issue":"34","key":"2020102211371717600_B25","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"2020102211371717600_B26","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1111\/cas.13398","article-title":"Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011: A nationwide survey","volume":"108","author":"Nosaka","year":"2017","journal-title":"Cancer Sci"},{"issue":"34","key":"2020102211371717600_B27","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter phase II study of lenalidomide in relapsed or recurrent adult t-cell leukemia\/lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J Clin Oncol"},{"issue":"14","key":"2020102211371717600_B28","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.2011.38.2101","article-title":"Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma","volume":"30","author":"Katsuya","year":"2012","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020102211371717600_B29","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bjh.12962","article-title":"Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A)","volume":"166","author":"Fukushima","year":"2014","journal-title":"Br J Haematol"},{"issue":"28","key":"2020102211371717600_B30","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","article-title":"Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality","volume":"34","author":"Fuji","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020102211371717600_B31","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/nrc2111","article-title":"Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation","volume":"7","author":"Matsuoka","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"2020102211371717600_B32","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","article-title":"Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma","volume":"15","author":"Ishitsuka","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5609","key":"2020102211371717600_B33","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"issue":"6","key":"2020102211371717600_B34","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","article-title":"Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor","volume":"30","author":"Miyara","year":"2009","journal-title":"Immunity"},{"issue":"9","key":"2020102211371717600_B35","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/ijc.22536","article-title":"Regulatory T-cell function of adult T-cell leukemia\/lymphoma cells","volume":"120","author":"Yano","year":"2007","journal-title":"Int J Cancer"},{"issue":"5","key":"2020102211371717600_B36","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1349-7006.1988.tb00028.x","article-title":"Serum soluble interleukin-2 receptor levels in patients with adult T-cell leukemia and human T-cell leukemia\/lymphoma virus type-I seropositive healthy carriers","volume":"79","author":"Motoi","year":"1988","journal-title":"Jpn J Cancer Res"},{"issue":"10","key":"2020102211371717600_B37","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1111\/j.1349-7006.2012.02371.x","article-title":"Tax is a potential molecular target for immunotherapy of adult T-cell leukemia\/lymphoma","volume":"103","author":"Suzuki","year":"2012","journal-title":"Cancer Sci"},{"issue":"1","key":"2020102211371717600_B38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4049\/jimmunol.1202692","article-title":"Autologous Tax-specific CTL therapy in a primary adult T cell leukemia\/lymphoma cell-bearing NOD\/Shi-scid, IL-2R\u03b3null mouse model","volume":"191","author":"Masaki","year":"2013","journal-title":"J Immunol"},{"issue":"3","key":"2020102211371717600_B39","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.13302","article-title":"Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia\/lymphoma in a pilot study","volume":"169","author":"Suehiro","year":"2015","journal-title":"Br J Haematol"},{"issue":"8","key":"2020102211371717600_B40","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1111\/cas.13654","article-title":"Human T-cell lymphotropic\/leukemia virus type 1 (HTLV-1) Tax-specific T-cell exhaustion in HTLV-1-infected individuals","volume":"109","author":"Masaki","year":"2018","journal-title":"Cancer Sci"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/20\/5133\/1778946\/advancesadv2020003053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/20\/5133\/1778946\/advancesadv2020003053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T15:39:16Z","timestamp":1603381156000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/20\/5133\/469704\/Mogamulizumab-for-adult-Tcell-leukemialymphoma-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":40,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2020,10,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020003053","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,22]]}}}